186380-62-1|CGP64222|CGP64222|-范德生物科技公司

CGP64222

NMR下载 COA and HPLC MSDS下载
names：
CGP64222
CAS号：
186380-62-1
MDL Number：
MF(分子式)： C58H107N25O9 MW(分子量)： 1298.66
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(2S)-1-(2-((R)-6-amino-2-((S)-6-amino-2-(1,1-diamino-6-((6-aminohexyl)glycyl)-12-benzyl-9,15-bis(3-((diaminomethylene)amino)propyl)-8,11,14-trioxo-2,6,9,12,15-pentaazaheptadec-1-en-17-amido)hexanamido)hexanamido)-5-((diaminomethylene)amino)pentanoyl)pyrrolidine-2-carboxamide
英文别名	CGP64222; CGP-64222; CGP 64222;
CAS号	186380-62-1
Inchi	InChI=1S/C58H107N25O9/c59-23-8-1-2-11-26-71-35-47(85)80(32-15-29-74-57(67)68)38-48(86)81(33-16-30-75-58(69)70)39-50(88)82(36-41-17-4-3-5-18-41)40-49(87)79(31-14-28-73-56(65)66)37-46(84)76-42(19-6-9-24-60)52(90)77-43(20-7-10-25-61)53(91)78-44(21-12-27-72-55(63)64)54(92)83-34-13-22-45(83)51(62)89/h3-5,17-18,42-45,71H,1-2,6-16,19-40,59-61H2,(H2,62,89)(H,76,84)(H,77,90)(H,78,91)(H4,63,64,72)(H4,65,66,73)(H4,67,68,74)(H4,69,70,75)/t42-,43+,44?,45-/m0/s1
InchiKey	PHIRWRJXMDCHJF-NKRIFVGSSA-N
分子式 Formula	C58H107N25O9
分子量 Molecular Weight	1298.66
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	CGP64222(CAS:186380-62-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	CGP64222 is a peptoid Tat/transactivation response element inhibitor. It inhibits human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Fu J, Xia A, Dai Y, Qi X. Design-Based Peptidomimetic Ligand Discovery to Target HIV TAR RNA Using Comparative Analysis of Different Docking Methods. Curr HIV Res. 2016;14(6):476-483. PubMed PMID: 27450546.

[2]Bai RJ, Liu XY. [Transactivation of HIV-1 transcription and inhibitors]. Yao Xue Xue Bao. 2006 Apr;41(4):289-95. Review. Chinese. PubMed PMID: 16856471.

[3] Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des. 2005;11(14):1805-43. Review. PubMed PMID: 15892677.

[4] Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem. 2004;4(9):883-93. Review. PubMed PMID: 15134547.

[5] De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):258-75. Review. PubMed PMID: 12084468.

6: De Clercq E, Schols D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother. 2001;12 Suppl 1:19-31. PubMed PMID: 11594685.7: De Clercq E. New developments in anti-HIV chemotherapy. Curr Med Chem. 2001 Nov;8(13):1543-72. Review. PubMed PMID: 11562282.8: De Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev Med Virol. 2000 Jul-Aug;10(4):255-77. Review. Erratum in: Rev Med Virol 2000 Sep-Oct;10(5):349. PubMed PMID: 10891872.9: De Clercq E. The emerging role of fusion inhibitors in HIV infection. Drugs R D. 1999 Nov;2(5):321-31. Review. PubMed PMID: 10728472.10: Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, Hamy F, Klimkait T, de Clercq E, VanDamme AM. A second target for the peptoid Tat/transactivation response element inhibitor CGP6422

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开